Compare DexCom, Inc. (DXCM) vs Vital Farms Inc (VITL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Vital Farms Inc — how do they compare? DexCom, Inc. trades at $77.86 (market cap $28.06B), while Vital Farms Inc trades at $13.43 (market cap $581.88M). The key difference: DexCom, Inc. is far larger — about 48.2× Vital Farms Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, Vital Farms Inc nearer its low. Which is the better fit depends on your goals.
| DXCM | VITL | |
|---|---|---|
Market Cap | $28.06B | $581.88M |
Sector | Health | Consumer Staples |
52-Week High | $89.53 | $52.41 |
52-Week Low | $54.84 | $8.28 |
Enterprise Value | $27.03B | $584.69M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
Vital Farms (VITL) trades at $13.54, up 3.28% with a bullish technical signal from moving averages and oscillators. The company shows solid fundamentals with a P/E of 13.06, P/S of 0.79, and strong profitability margins (ROE 15.44%, net margin 6.1%). Recent earnings have been mixed with Q3 2025 beating expectations but Q1 2026 missing, while analyst consensus remains positive with 56% buy ratings and a $13.50 price target.
The outlook suggests potential upside to the $16 high target given reasonable valuation and profitability, but risks include ongoing class action lawsuits, negative cash flow trends, and earnings volatility. Revenue growth is projected to slow from 2025 to 2026 with profit margins compressing from 8.72% to 6.1%, indicating execution challenges ahead.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Vital Farms Inc
Vital Farms is a leading provider of ethically produced, pasture-raised eggs and butter in the United States. Operating as a Public Benefit Corporation, it manages a network of over 650 family farms to deliver high-welfare food products. It leverages a scalable 'asset-light' partnership model that prioritizes transparency and animal welfare to meet the growing consumer demand for clean-label and sustainable food sources.
Read more on VITL →
